Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A new study shows that weight loss medication patients can experience hunger, eat well-balanced meals, and still make significant progress ...

GLP-1s have been a hot topic, now people are raising concerns about the side effects. From loose skin and dull complexions to hair loss and more. Aesthetic ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...